Source: MarketScreener

Meridian Bioscience: Meridian submits Curian analyzer and the Curian HpSA assay to the FDA

(marketscreener.com) CINCINNATI, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has submitted Curian and the Curian HpSA assay to the FDA for review. This platform and assay are designed to specifically detect Helicobacter pylori antigens in human stool using fluorescent lateral flow...http://www.marketscreener.com/MERIDIAN-BIOSCIENCE-INC-11296/news/Meridian-submits-Curian-trade-analyzer-and-the-Curian-trade-HpSA-assay-to-the-FDA-29526346/?utm_medium=RSS&utm_content=20191106

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Meridian Bioscience's latest SEC filings

Annual Revenue

Based on data from Meridian Bioscience's latest SEC filings

Employees

John P. Kenny's photo - CEO of Meridian Bioscience

CEO

John P. Kenny

CEO Approval Rating

68/100

Meridian is a life science company that manufactures and distributes diagnostic test kits, rare reagents, specialty biol... Read more